The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Accuray P/E ratio is -14.2. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Accuray’s P/E ratio

## What is Accuray P/E Ratio?

Accuray’s P / E ratio is -14.2, which represents a 52.2% decrease from the same period last year. their average P / E ratio is 85.59 and their 5-year average is -15.41.

## What is Accuray Net EPS?

Accuray’s net earnings for the most recent quarter were -0.14$, which represents a 100.0% decrease from the same period last year.

## Who are Accuray Competitors?

Based on Jika.io AI model, Novacyt S.A., Asensus Surgical, AVITA Medical, Electromed, iCAD, NeuroPace, Opsens, SANUWAVE Health are considered to be Accuray’s competitors because the companies operate within the same industry as Accuray and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Accuray.

## Who is Accuray’s Biggest competitor?

Accuray’s biggest competitor is Novacyt S.A. based on the AI model of Jika.io. it has a similar market capitalization to Accuray in the industry, it dominates a similar share of the market as Accuray, and it provides and markets very similar services.

## What industry is Accuray in?

Accuray is part of the Medical Devices industry and the Healthcare sector.

## Accuray vs Novacyt S.A.

Market Cap: Accuray’s Market Cap of 186532416 is higher than Novacyt S.A. Market Cap of 93226584.

Average Volume: Accuray’s Average Volume of 1.261M is lower than Novacyt S.A. Average Volume of 414270.0.

Beta: Accuray’s Beta of 1.94 is higher than Novacyt S.A. Beta of -2.93.

Revenue: Accuray’s Revenue of 396.289M is lower than Novacyt S.A. Revenue of 95.78M.

Net Income: Accuray’s Net Income of -6.311M is lower than Novacyt S.A. Net Income of -9.728M.

Gross Profit: Accuray’s Gross Profit of 159.507M is lower than Novacyt S.A. Gross Profit of 29.678M.

Ebitda: Accuray’s Ebitda of 18.723M is higher than Novacyt S.A. Ebitda of -1.708M.

P/B Ratio: Accuray’s P/B Ratio of 3.57 is higher than Novacyt S.A. P/B Ratio of 0.66.

ROE: Accuray’s ROE of -0.24 is lower than Novacyt S.A. ROE of 0.0.

ROA: Accuray’s ROA of -0.03 is lower than Novacyt S.A. ROA of 0.0.

Return On Capital Employed: Accuray’s Return On Capital Employed of 0.04 is higher than Novacyt S.A. Return On Capital Employed of 0.0.

Assets (Total): Accuray’s Assets (Total) of 480.098M is higher than Novacyt S.A. Assets (Total) of 183.697M.

Debt (Total): Accuray’s Debt (Total) of 199.407M is higher than Novacyt S.A. Debt (Total) of 1.87M.

Shareholders Equity: Accuray’s Shareholders Equity of 68.84M is higher than Novacyt S.A. Shareholders Equity of 141.815M.

## Accuray vs Asensus Surgical

Market Cap: Accuray’s Market Cap of 186532416 is higher than Asensus Surgical Market Cap of 93780432.

Average Volume: Accuray’s Average Volume of 1.261M is lower than Asensus Surgical Average Volume of 3.086M.

Beta: Accuray’s Beta of 1.94 is higher than Asensus Surgical Beta of 1.68.

Revenue: Accuray’s Revenue of 396.289M is lower than Asensus Surgical Revenue of 8.232M.

Net Income: Accuray’s Net Income of -6.311M is lower than Asensus Surgical Net Income of -62.462M.

Gross Profit: Accuray’s Gross Profit of 159.507M is higher than Asensus Surgical Gross Profit of -2.864M.

Ebitda: Accuray’s Ebitda of 18.723M is higher than Asensus Surgical Ebitda of -48.946M.

P/E Ratio: Accuray’s P/E Ratio of -14.2 is higher than Asensus Surgical P/E Ratio of -1.46.

P/S Ratio: Accuray’s P/S Ratio of 0.43 is lower than Asensus Surgical P/S Ratio of 12.97.

P/B Ratio: Accuray’s P/B Ratio of 3.57 is higher than Asensus Surgical P/B Ratio of 0.62.

P/FCF Ratio: Accuray’s P/FCF Ratio of 43.65 is higher than Asensus Surgical P/FCF Ratio of -1.97.

ROE: Accuray’s ROE of -0.24 is lower than Asensus Surgical ROE of -0.37.

ROA: Accuray’s ROA of -0.03 is lower than Asensus Surgical ROA of -0.39.

Return On Capital Employed: Accuray’s Return On Capital Employed of 0.04 is higher than Asensus Surgical Return On Capital Employed of -0.43.

Gross Profit Margin: Accuray’s Gross Profit Margin of 0.37 is higher than Asensus Surgical Gross Profit Margin of -0.36.

Assets (Total): Accuray’s Assets (Total) of 480.098M is higher than Asensus Surgical Assets (Total) of 186.473M.

Debt (Total): Accuray’s Debt (Total) of 199.407M is higher than Asensus Surgical Debt (Total) of 12.061M.

Shareholders Equity: Accuray’s Shareholders Equity of 68.84M is higher than Asensus Surgical Shareholders Equity of 169.246M.

## Accuray vs AVITA Medical

Market Cap: Accuray’s Market Cap of 186532416 is lower than AVITA Medical Market Cap of 249556000.

Average Volume: Accuray’s Average Volume of 1.261M is lower than AVITA Medical Average Volume of 350.0.

Beta: Accuray’s Beta of 1.94 is higher than AVITA Medical Beta of 0.73.

Revenue: Accuray’s Revenue of 396.289M is higher than AVITA Medical Revenue of 29.232M.

Net Income: Accuray’s Net Income of -6.311M is higher than AVITA Medical Net Income of -26.583M.

Gross Profit: Accuray’s Gross Profit of 159.507M is lower than AVITA Medical Gross Profit of 23.283M.

Ebitda: Accuray’s Ebitda of 18.723M is higher than AVITA Medical Ebitda of -25.808M.

P/E Ratio: Accuray’s P/E Ratio of -14.2 is lower than AVITA Medical P/E Ratio of -4.44.

P/S Ratio: Accuray’s P/S Ratio of 0.43 is lower than AVITA Medical P/S Ratio of 7.77.

P/B Ratio: Accuray’s P/B Ratio of 3.57 is higher than AVITA Medical P/B Ratio of 2.55.

P/FCF Ratio: Accuray’s P/FCF Ratio of 43.65 is higher than AVITA Medical P/FCF Ratio of -8.73.

ROE: Accuray’s ROE of -0.24 is lower than AVITA Medical ROE of -0.73.

ROA: Accuray’s ROA of -0.03 is lower than AVITA Medical ROA of -0.53.

Return On Capital Employed: Accuray’s Return On Capital Employed of 0.04 is higher than AVITA Medical Return On Capital Employed of -0.27.

Gross Profit Margin: Accuray’s Gross Profit Margin of 0.37 is lower than AVITA Medical Gross Profit Margin of 0.79.

Assets (Total): Accuray’s Assets (Total) of 480.098M is higher than AVITA Medical Assets (Total) of 125.501M.

Debt (Total): Accuray’s Debt (Total) of 199.407M is lower than AVITA Medical Debt (Total) of 878000.0.

Shareholders Equity: Accuray’s Shareholders Equity of 68.84M is higher than AVITA Medical Shareholders Equity of 115.655M.

## Accuray vs Electromed

Market Cap: Accuray’s Market Cap of 186532416 is higher than Electromed Market Cap of 81554920.

Average Volume: Accuray’s Average Volume of 1.261M is lower than Electromed Average Volume of 9140.0.

Beta: Accuray’s Beta of 1.94 is higher than Electromed Beta of 0.59.

Revenue: Accuray’s Revenue of 396.289M is higher than Electromed Revenue of 35.756M.

Net Income: Accuray’s Net Income of -6.311M is lower than Electromed Net Income of 2.362M.

Gross Profit: Accuray’s Gross Profit of 159.507M is lower than Electromed Gross Profit of 27.305M.

Ebitda: Accuray’s Ebitda of 18.723M is lower than Electromed Ebitda of 3.777M.

P/E Ratio: Accuray’s P/E Ratio of -14.2 is lower than Electromed P/E Ratio of 36.85.

P/S Ratio: Accuray’s P/S Ratio of 0.43 is lower than Electromed P/S Ratio of 2.03.

P/B Ratio: Accuray’s P/B Ratio of 3.57 is higher than Electromed P/B Ratio of 2.38.

P/FCF Ratio: Accuray’s P/FCF Ratio of 43.65 is higher than Electromed P/FCF Ratio of -85.92.

ROE: Accuray’s ROE of -0.24 is lower than Electromed ROE of 0.07.

ROA: Accuray’s ROA of -0.03 is lower than Electromed ROA of 0.06.

Return On Capital Employed: Accuray’s Return On Capital Employed of 0.04 is lower than Electromed Return On Capital Employed of 0.09.

Gross Profit Margin: Accuray’s Gross Profit Margin of 0.37 is lower than Electromed Gross Profit Margin of 0.76.

Assets (Total): Accuray’s Assets (Total) of 480.098M is higher than Electromed Assets (Total) of 37.109M.

Debt (Total): Accuray’s Debt (Total) of 199.407M is higher than Electromed Debt (Total) of 0.0.

Shareholders Equity: Accuray’s Shareholders Equity of 68.84M is higher than Electromed Shareholders Equity of 32.416M.

## About Accuray

Accuray Incorporated designs, develops, manufactures and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China and the rest of the Asia Pacific region. it offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas and kidney. the company also provides the TomoTherapy System, including the Radixact System, which is an integrated radiation therapy system designed for the treatment of a variety of cancer types. in addition, it offers customer support, installation, training and other professional services after the contract. the company primarily markets its products directly to customers, including hospitals and standalone treatment facilities, through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States, and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was founded in 1990 and has its headquarters in Sunnyvale, California.